Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0

In this expert discussion at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC), Yehuda Handelsman, MD, medical director and principal investigator for The Metabolic Institute of America (TMIOA) and chair and program director for WCIRDC, discussed key insights from this year’s meeting, including the foundational role of insulin resistance in cardiometabolic, renal, and hepatic complications. Handelsman highlighted the multifaceted nature of insulin resistance, exploring its causes—such as elevated cortisol levels—and its link to comorbidities like kidney disease and bone health, particularly involving parathyroid hormone.

Handelsman also introduced the Diabetes CardioRenal Metabolic (DCRM) 2.0 Recommendations, an updated, internationally focused guideline designed to address the interconnected nature of diabetes, cardiovascular, renal, and metabolic diseases. Unlike traditional guidelines that are discipline-specific, DCRM 2.0 was developed in collaboration by over 50 specialists, including endocrinologists, cardiologists, nephrologists, and primary care physicians. He noted this version is an expansion of its 2022 predecessor by incorporating new areas such as pulmonary disease, inflammation, obesity, and technology while maintaining a streamlined, easy-to-follow format for diagnosis, prevention, and management of multi-system conditions.

Since its publication, Handlesman indicated DCRM 2.0 has gained significant global traction, becoming the most-cited paper in the journal’s history. In particular, Handelsman emphasized its international adaptability, with presentations already occurring across Europe, Asia, and major conferences such as the American Heart Association (AHA) Scientific Sessions 2024. Overall, the comprehensive recommendations seek to provide practical, integrated care frameworks to improve outcomes for patients with complex cardiometabolic diseases.

Relevant disclosures for Handelsman include Amarin, Amgen, BI-Lilly, Novo Nordisk, Sanofi, and others.

Reference

Handlesman Y. Everything IR - Cardiometabolic Diseases. Presented at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC). Los Angeles, California. December 12-14, 2024.

Handlesman Y. DRCM 2.0. Presented at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC). Los Angeles, California. December 12-14, 2024.